Join to view full profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Dr. Goetz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
University of MichiganResidency, Internal Medicine, 1996 - 1999- University of MichiganInternship, Internal Medicine, 1996 - 1997
University of North Dakota School of Medicine and Health SciencesClass of 1996
Certifications & Licensure
MN State Medical License 1999 - 2026
MI State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017
- CMS Meaningful Use Stage 2 Certification Mayo Clinic Electronic Notes, Mayo Clinic, 2014-2017
- CMS Meaningful Use Stage 2 Certification Mayo Clinic Incorporate Lab Results, Mayo Clinic, 2014-2017
Clinical Trials
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
- Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
- Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Publications & Presentations
PubMed
- Endocrine Therapy Omission in Estrogen Receptor-Low (1-10%) Early Stage Breast Cancer: An Updated Analysis of the NCDB Database.Saskia J Leonard, Tanya L Hoskin, Grace M Choong, Matthew P Goetz, Judy C Boughey
Annals of Surgical Oncology. 2026-10-09 - ASO Visual Abstract: Neoadjuvant Dual Targeted HER2 Therapy and Neoadjuvant Chemo-Immunotherapy Is Associated with Improved Nodal pCR and Reduced Axillary Surgery.Saranya Prathibha, Tanya L Hoskin, Matthew P Goetz, Judy C Boughey
Annals of Surgical Oncology. 2026-09-28 - Neoadjuvant Dual-Targeted HER2 Therapy and Neoadjuvant Chemo-Immunotherapy is Associated with Improved Nodal pCR and Reduced Axillary Surgery.Saranya Prathibha, Tanya L Hoskin, Matthew P Goetz, Judy C Boughey
Annals of Surgical Oncology. 2026-09-21
Journal Articles
- ERβ-Mediated Induction of Cystatins Results in Suppression of TGFβ Signaling and Inhibition of Triple-Negative Breast Cancer MetastasisMatthew P Goetz, James N Ingle, Proceedings of the National Academy of Sciences
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerMatthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine
Press Mentions
Phase 3 Failure for Breast Cancer Treatment at ASCO 2026 Raises QuestionsJune 4th, 2026- Mayo Clinic Partners in Groundbreaking Study Demonstrating Enhanced Survival Rates for Early Breast Cancer PatientsOctober 23rd, 2025
- Mayo Clinic Leads 4 Decades of Advances in Breast Cancer CareOctober 2nd, 2025
Grant Support
- Mayo Clinic Breast Cancer SPOREMAYO CLINIC ROCHESTER2005–2027
- Tamoxifen Biotransformation Pathway PharmacogenomicsNational Cancer Institute2008–2011
Committees
- Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
